(VIANEWS) – Celsius Holdings (CELH), Genmab (GMAB), BlackRock Capital Investment Corporation (BKCC) are the highest sales growth and return on equity stocks on this list.
Here is a list of stocks with an above 5% expected next quarter sales growth, and a 3% or higher return on equity. May these stocks be a good medium-term investment option?
1. Celsius Holdings (CELH)
77.6% sales growth and 23.23% return on equity
Celsius Holdings, Inc. develops, processes, markets, distributes, and sells functional drinks and liquid supplements in the United States and internationally. The company offers various carbonated and non-carbonated functional energy drinks under the CELSIUS Originals name; dietary supplement in carbonated flavors, including apple jack'd, orangesicle, inferno punch, cherry lime, blueberry pomegranate, strawberry dragon fruit, tangerine grapefruit, and jackfruit under the CELSIUS HEAT name; and branched-chain amino acids functional energy drink that fuels muscle recovery under the CELSIUS BCCA+ENERGY name. It also provides CELSIUS On-the-Go, a powdered form of the active ingredients in functional energy drinks in individual On-The-Go packets and canisters; and sparkling grapefruit, cucumber lime, and orange pomegranate, as well as pineapple coconut, watermelon berry, and strawberries and cream non-carbonated functional energy drinks under the CELSIUS Sweetened name; and CELSIUS ready-to drink products. It distributes its products through direct-to-store delivery distributors and direct to retailers, include supermarkets, convenience stores, drug stores, nutritional stores, and mass merchants, as well as health clubs, spas, gyms, the military, and e-commerce websites. The company was formerly known as Vector Ventures, Inc. and changed its name to Celsius Holdings, Inc. in January 2007. Celsius Holdings, Inc. was founded in 2004 and is headquartered in Boca Raton, Florida.
Earnings Per Share
As for profitability, Celsius Holdings has a trailing twelve months EPS of $0.77.
PE Ratio
Celsius Holdings has a trailing twelve months price to earnings ratio of 113.69. Meaning, the purchaser of the share is investing $113.69 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 23.23%.
Previous days news about Celsius Holdings(CELH)
- According to Zacks on Wednesday, 6 March, "Investors interested in the Consumer Staples sector may want to keep a close eye on BRF and Celsius Holdings Inc. as they attempt to continue their solid performance.", "Another Consumer Staples stock, which has outperformed the sector so far this year, is Celsius Holdings Inc. (CELH Quick QuoteCELH – Free Report) . "
- Celsius holdings inc. (celh) upgraded to buy: here's why. According to Zacks on Wednesday, 6 March, "Analysts have been steadily raising their estimates for Celsius Holdings Inc. Over the past three months, the Zacks Consensus Estimate for the company has increased 9.8%.", "The upgrade of Celsius Holdings Inc. to a Zacks Rank #2 positions it in the top 20% of the Zacks-covered stocks in terms of estimate revisions, implying that the stock might move higher in the near term."
2. Genmab (GMAB)
17.6% sales growth and 14.78% return on equity
Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.
Earnings Per Share
As for profitability, Genmab has a trailing twelve months EPS of $0.96.
PE Ratio
Genmab has a trailing twelve months price to earnings ratio of 30.15. Meaning, the purchaser of the share is investing $30.15 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 14.78%.
Yearly Top and Bottom Value
Genmab’s stock is valued at $28.94 at 19:22 EST, way under its 52-week high of $42.99 and above its 52-week low of $26.32.
3. BlackRock Capital Investment Corporation (BKCC)
6.2% sales growth and 4.85% return on equity
BlackRock Capital Investment Corporation, formerly known as BlackRock Kelso Capital Corporation, is a Business Development Company specializing in investments in middle market companies. The fund invests in all industries. It prefers to invest between $10 million and $50 million and can invest more or less in companies with EBITDA or operating cash flow between $10 million and $50 million. The fund invests in the form of senior and junior secured, unsecured, and subordinated debt securities and loans including cash flow, asset backed, and junior lien facilities and equity securities. It's equity investments can be structured in the form of warrants, preferred stock, common equity co-investments, and direct investments in common stock. The fund's debt investments are principally structured to provide for current cash interest and to a lesser extent non-cash interest, particularly with subordinated debt investments, through a pay-in-kind (PIK) feature. It can also make non-control investments.
Earnings Per Share
As for profitability, BlackRock Capital Investment Corporation has a trailing twelve months EPS of $0.22.
PE Ratio
BlackRock Capital Investment Corporation has a trailing twelve months price to earnings ratio of 16.73. Meaning, the purchaser of the share is investing $16.73 for every dollar of annual earnings.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is 4.85%.
Revenue Growth
Year-on-year quarterly revenue growth grew by 33.2%, now sitting on 77.51M for the twelve trailing months.
